Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 18

1.

WFUMB Safety Symposium on Ultrasound Contrast Agents: clinical applications and safety concerns.

Blomley M, Claudon M, Cosgrove D.

Ultrasound Med Biol. 2007 Feb;33(2):180-6. Review. No abstract available.

PMID:
17254696
2.

Imaging and quantification of myocardial perfusion using real-time three-dimensional echocardiography.

Toledo E, Lang RM, Collins KA, Lammertin G, Williams U, Weinert L, Bolotin G, Coon PD, Raman J, Jacobs LD, Mor-Avi V.

J Am Coll Cardiol. 2006 Jan 3;47(1):146-54. Epub 2005 Dec 13.

3.

Influence of contrast agent dose and ultrasound exposure on cardiomyocyte injury induced by myocardial contrast echocardiography in rats.

Miller DL, Li P, Dou C, Gordon D, Edwards CA, Armstrong WF.

Radiology. 2005 Oct;237(1):137-43.

PMID:
16183929
4.

Targeted contrast agents for magnetic resonance imaging and ultrasound.

Morawski AM, Lanza GA, Wickline SA.

Curr Opin Biotechnol. 2005 Feb;16(1):89-92. Review.

PMID:
15722020
5.

UnitedHealth snags Definity.

Benko LB.

Mod Healthc. 2004 Dec 6;34(49):8-9. No abstract available.

PMID:
15624677
6.

Contrast echocardiography: new agents.

Miller AP, Nanda NC.

Ultrasound Med Biol. 2004 Apr;30(4):425-34. Review.

PMID:
15121243
7.

Ultrasound contrast imaging research.

Averkiou M, Powers J, Skyba D, Bruce M, Jensen S.

Ultrasound Q. 2003 Mar;19(1):27-37. Review.

PMID:
12970614
8.

Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: the key role of perfluorochemicals.

Schutt EG, Klein DH, Mattrey RM, Riess JG.

Angew Chem Int Ed Engl. 2003 Jul 21;42(28):3218-35. Review.

PMID:
12876730
9.

Influence of contrast ultrasonography with perflutren lipid microspheres on microvessel injury.

Kobayashi N, Yasu T, Yamada S, Kudo N, Kuroki M, Miyatake K, Kawakami M, Saito M.

Circ J. 2003 Jul;67(7):630-6.

10.

The behaviour of individual contrast agent microbubbles.

Sboros V, Moran CM, Pye SD, McDicken WN.

Ultrasound Med Biol. 2003 May;29(5):687-94.

PMID:
12754068
11.
12.

In vitro acoustic characterisation of four intravenous ultrasonic contrast agents at 30 MHz.

Moran CM, Watson RJ, Fox KA, McDicken WN.

Ultrasound Med Biol. 2002 Jun;28(6):785-91.

PMID:
12113791
13.

Contrast material-enhanced abdominal US examinations with DMP 115 (DEFINITY) provides additional diagnostic information with potential for changes in patient management.

Rosenberg ML, Carpenter AP; Phase III DEFINITY Clinical Investigators.

Acad Radiol. 2002 May;9 Suppl 1:S243-5. No abstract available.

PMID:
12019880
14.

Oxygen carriers ("blood substitutes")--raison d'etre, chemistry, and some physiology.

Riess JG.

Chem Rev. 2001 Sep;101(9):2797-920. Review. No abstract available.

PMID:
11749396
15.

Real-time myocardial blood flow imaging in normal human beings with the use of myocardial contrast echocardiography.

Murthy TH, Li P, Locvicchio E, Baisch C, Dairywala I, Armstrong WF, Vannan M.

J Am Soc Echocardiogr. 2001 Jul;14(7):698-705.

PMID:
11447415
16.

Grey-scale contrast enhancement in rabbit liver with DMP115 at different acoustic power levels.

Maruyama H, Matsutani S, Saisho H, Kamiyama N, Yuki H, Miyata K.

Ultrasound Med Biol. 2000 Nov;26(9):1429-38.

PMID:
11179617
17.

Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images.

Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS.

Am J Cardiol. 2000 Sep 15;86(6):669-74.

PMID:
10980221
18.

Results of the phase III trials with Imagent GI as an oral magnetic resonance contrast agent.

Mattrey RF, Trambert MA, Brown JJ, Bruneton JN, Young SW, Schooley GL.

Invest Radiol. 1991 Nov;26 Suppl 1:S65-6; discussion S71. No abstract available.

PMID:
1808151

Supplemental Content

Support Center